10 free, board-style Endocrinology questions for the PANCE, each with the correct answer and a complete explanation. No email, no account required.
Endocrinology is 6% of the PANCE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.
Question 1EndocrineMedium
A 48-year-old woman is evaluated for hypertension that has remained difficult to control on two agents. She takes no diuretics. Blood pressure is 168/104 mm Hg and serum potassium is 3.1 mEq/L with high-normal serum sodium. The plasma aldosterone-to-renin ratio is markedly elevated at 40. Renal function is normal and there are no cushingoid features. Which of the following is the most likely diagnosis?
APrimary hyperaldosteronism
BEssential hypertension
CPheochromocytoma
DRenovascular hypertension
EGitelman syndrome
Reveal answer & full explanation
Correct answer: A — Primary hyperaldosteronism
APrimary hyperaldosteronism✓
BEssential hypertension
CPheochromocytoma
DRenovascular hypertension
EGitelman syndrome
Why Primary hyperaldosteronism is correct
Resistant hypertension with spontaneous (non-diuretic) hypokalemia and a markedly elevated aldosterone-to-renin ratio is the classic screen-positive picture for primary hyperaldosteronism (Conn syndrome).
Autonomous aldosterone secretion drives sodium retention (hypertension, high-normal serum sodium) and renal potassium wasting (hypokalemia) while suppressing renin, producing the high ratio.
Under the 2025 Endocrine Society guideline, a positive screen is a suppressed renin with an aldosterone of 10 ng/dL or more by immunoassay and an aldosterone-to-renin ratio above 20. In a patient who wants surgery, a suppression test (saline infusion or fludrocortisone) is added only when the probability of lateralizing disease is intermediate; adrenal CT then precedes adrenal venous sampling to lateralize. A patient not pursuing surgery can start a mineralocorticoid receptor antagonist on the screening result.
Why the others are wrong
Essential hypertension — does not cause spontaneous hypokalemia or an elevated aldosterone-to-renin ratio. Trap: premature closure on the most common cause of hypertension while ignoring the potassium and the ratio.
Pheochromocytoma — catecholamine excess produces episodic hypertension with headache, palpitations, and diaphoresis; it does not suppress renin or raise the aldosterone-to-renin ratio, and spontaneous hypokalemia is not part of the syndrome. Trap: reaching for any secondary cause of resistant hypertension without matching the specific electrolyte and hormone pattern.
Renovascular hypertension — causes secondary hyperaldosteronism with HIGH renin, so the aldosterone-to-renin ratio is low or normal, not 40. Trap: confusing primary (low-renin) with secondary (high-renin) aldosteronism.
Gitelman syndrome — a salt-wasting distal tubulopathy that mimics chronic thiazide use, so it is tempting for spontaneous hypokalemia in an adult who takes no diuretics, but the volume loss raises renin and leaves blood pressure normal or low, so it explains neither resistant hypertension nor an aldosterone-to-renin ratio of 40. Trap: matching the potassium while ignoring the blood pressure and the renin.
Question 2EndocrineMedium
A 38-year-old man presents with low libido, erectile dysfunction, and fatigue for 8 months. He also reports decreased morning erections and difficulty concentrating at work. PMH is unremarkable and he takes no medications. Exam shows small soft testes, decreased body hair, and mild gynecomastia. An 8 AM total testosterone drawn fasting is 180 ng/dL (normal 300-1000), confirmed low on a repeat morning sample. Which of the following is the most appropriate next step in his evaluation?
ASerum prolactin level
BSerum estradiol and DHEA-S
CKaryotype analysis
DPituitary MRI with contrast
ESerum LH and FSH levels
Reveal answer & full explanation
Correct answer: E — Serum LH and FSH levels
ASerum prolactin level
BSerum estradiol and DHEA-S
CKaryotype analysis
DPituitary MRI with contrast
ESerum LH and FSH levels✓
Why Serum LH and FSH levels is correct
Biochemically confirmed hypogonadism requires two early-morning total testosterone measurements, which this patient has
The next step is to determine whether the defect is primary (testicular) or secondary (hypothalamic-pituitary) by measuring LH and FSH
This LH/FSH branch point directs the etiologic workup: karyotype when gonadotropins are high (especially with testes <6 mL); prolactin, iron saturation and other pituitary hormone testing, with pituitary MRI in selected cases, when they are low or inappropriately normal
Why the others are wrong
Serum estradiol and DHEA-S — estradiol is reasonable in a testosterone-deficient man with gynecomastia before testosterone therapy is started (AUA 2018, validity confirmed 2024), but it does not separate testicular from hypothalamic-pituitary failure; DHEA-S is an adrenal androgen with no role in the standard evaluation of male hypogonadism. Ordering these now skips the branch-point test.
Karyotype analysis — appropriate only after primary hypogonadism with elevated FSH is documented and Klinefelter syndrome is suspected; right-test-wrong-step before gonadotropins are known
Pituitary MRI with contrast — reserved for confirmed secondary hypogonadism, particularly with markedly low testosterone (<150 ng/dL), elevated prolactin, visual field defects, or other anterior pituitary hormone abnormalities, not before LH/FSH are known; anchoring on the central-cause possibility before localizing. Here, testosterone of 180 ng/dL is above the <150 ng/dL imaging threshold, no headache or visual symptoms are reported, and even if LH were low, prolactin and pituitary hormone testing would come before imaging (Endocrine Society 2018).
Serum prolactin level — tempting because hyperprolactinemia causes low libido, erectile dysfunction, and sometimes gynecomastia, but prolactin belongs to the secondary-hypogonadism workup once LH and FSH come back low or inappropriately normal; ordering it first skips the branch-point test that decides whether a pituitary evaluation is needed at all.
Question 3EndocrineMedium
A 46-year-old man with a BMI of 38 kg/m2 presents to discuss pharmacologic weight management. His partner reports loud snoring with witnessed apneic pauses, and a recent polysomnogram showed an apnea-hypopnea index of 32 events/hour, consistent with moderate-to-severe obstructive sleep apnea. He has no diabetes and takes no medications. He asks specifically about a drug that has an FDA indication for his sleep disorder in addition to weight loss. Which of the following is the most appropriate pharmacologic agent for this patient?
ASemaglutide
BNaltrexone-bupropion
CTirzepatide
DPhentermine
ELiraglutide
Reveal answer & full explanation
Correct answer: C — Tirzepatide
ASemaglutide
BNaltrexone-bupropion
CTirzepatide✓
DPhentermine
ELiraglutide
Why Tirzepatide is correct
Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed for chronic weight management (Zepbound)
The FDA expanded its label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index alongside weight loss
It is the first drug with an FDA indication specifically for OSA, addressing both the metabolic and respiratory components of obesity-related disease
For this non-diabetic patient with a BMI of 38 kg/m2 and an apnea-hypopnea index of 32 events/hour who wants an agent labeled for his sleep disorder, tirzepatide is the only listed drug whose FDA label covers both weight management and OSA
Why the others are wrong
Semaglutide — GLP-1 receptor agonist approved for chronic weight management and cardiovascular risk reduction; it would help him lose weight but carries no FDA indication for OSA, so it does not meet his stated requirement — a buzzword trap assuming all incretin-based drugs share the same labels
Liraglutide — GLP-1 receptor agonist approved for weight loss and type 2 diabetes, with no OSA indication and less weight loss than tirzepatide; same incretin-class confusion
Phentermine — sympathomimetic appetite suppressant indicated only for short-term weight loss, with no OSA indication; a weight-loss buzzword trap that ignores both the chronicity of obesity management and the sleep-disorder requirement
Naltrexone-bupropion — combination of an opioid antagonist and bupropion approved for chronic weight management, so it fits his long-term obesity care, but it carries no FDA indication for OSA and does not meet his stated requirement; same trap of assuming any chronic anti-obesity agent covers obesity-related comorbidities.
Question 4EndocrineMedium
A 45-year-old patient with type 1 diabetes mellitus and Addison disease reports several weeks of increasingly frequent and severe hypoglycemic episodes, including two that required assistance, despite no change in the insulin regimen, diet, or activity level. Deficiency of which of the following hormones best explains the increased risk of hypoglycemia?
ACortisol
BGrowth hormone
CAldosterone
DThyroid hormone
ECorticotropin
Reveal answer & full explanation
Correct answer: A — Cortisol
ACortisol✓
BGrowth hormone
CAldosterone
DThyroid hormone
ECorticotropin
Why Cortisol is correct
Cortisol is a key counter-regulatory hormone that stimulates hepatic gluconeogenesis and glycogenolysis and supports the glycemic response to falling glucose
In Addison disease the adrenal cortex fails, so cortisol deficiency removes this defense and blunts the counter-regulatory response to insulin-induced hypoglycemia
Combined with exogenous insulin in type 1 diabetes, this produces more frequent, severe, and prolonged hypoglycemia even when the insulin dose is unchanged
Worsening or unexplained hypoglycemia in a person with type 1 diabetes should prompt evaluation for concurrent adrenal insufficiency
Why the others are wrong
Aldosterone — the mineralocorticoid also lost in Addison disease, but it regulates sodium, potassium, and volume; its deficiency causes hyponatremia, hyperkalemia, and hypotension, not hypoglycemia; confused-with trap (right disease, wrong hormone)
Thyroid hormone — deficiency produces a hypometabolic state and is not deficient in this patient, so it does not explain the episodes; buzzword trap linking any endocrine deficiency to glucose
Growth hormone — a counter-regulatory hormone whose deficiency can cause hypoglycemia in young children, but it is not deficient in Addison disease and does not explain this picture; anchoring on 'counter-regulatory' without integrating the diagnosis
Corticotropin — the pituitary hormone that drives cortisol secretion, so its deficiency in secondary adrenal insufficiency can also cause hypoglycemia, but in Addison disease the adrenal cortex itself fails and corticotropin (ACTH) is elevated, not deficient; confused-with trap (primary vs secondary adrenal insufficiency).
Question 5EndocrineMedium
A 62-year-old man with type 2 diabetes mellitus is currently on semaglutide weekly and metformin, with an A1c of 8.1%. His PA plans to intensify therapy by adding one more oral agent. He drives a delivery truck for work and is concerned about losing his commercial license if he has hypoglycemic episodes. Which of the following oral agents carries the highest risk of hypoglycemia?
ASitagliptin
BPioglitazone
CAcarbose
DEmpagliflozin
EGlipizide
Reveal answer & full explanation
Correct answer: E — Glipizide
ASitagliptin
BPioglitazone
CAcarbose
DEmpagliflozin
EGlipizide✓
Why glipizide is correct
Sulfonylureas close ATP-sensitive potassium channels on pancreatic beta cells, triggering insulin release independent of glucose levels; this glucose-independent secretagogue effect makes hypoglycemia their signature adverse effect
Hypoglycemia risk is particularly high in older adults, those with renal impairment, or those who miss meals
Glipizide is a second-generation sulfonylurea with the highest hypoglycemia risk of the listed agents
Why the others are wrong
Pioglitazone — thiazolidinedione (TZD) that improves insulin sensitivity at the PPAR-gamma receptor; main risks are weight gain, edema, and fractures, not hypoglycemia
Sitagliptin — DPP-4 inhibitor that augments incretin levels in a glucose-dependent manner, so monotherapy carries minimal hypoglycemia risk
Empagliflozin — SGLT2 inhibitor that increases urinary glucose excretion independent of insulin and rarely causes hypoglycemia by itself
Acarbose — alpha-glucosidase inhibitor that delays intestinal carbohydrate absorption without stimulating insulin release, so it rarely causes hypoglycemia by itself; it is remembered for the rule that hypoglycemia occurring with it must be treated with glucose rather than sucrose, a combination-therapy caveat rather than a sign of high intrinsic risk
Additional high-yield points
Any agent stacked with insulin or a sulfonylurea inherits hypoglycemia risk, but among orals added to a GLP-1, the sulfonylurea is by far the most dangerous for a commercial driver
Question 6EndocrineMedium
A 48-year-old man presents to his primary care provider complaining that his wedding ring no longer fits and his shoe size has increased two sizes over the past 3 years. He also reports headaches, excessive sweating, and new snoring. On examination he has prominent supraorbital ridges, an enlarged jaw with widely spaced teeth, and large fleshy hands. Random serum insulin-like growth factor-1 (IGF-1) is markedly elevated, and growth hormone fails to suppress after a 75-gram oral glucose load. Which of the following is the most likely diagnosis?
ASevere insulin resistance syndrome
BPituitary lactotroph adenoma
CPituitary somatotroph adenoma
DPituitary corticotroph adenoma
EPrimary hypothyroidism
Reveal answer & full explanation
Correct answer: C — Pituitary somatotroph adenoma
ASevere insulin resistance syndrome
BPituitary lactotroph adenoma
CPituitary somatotroph adenoma✓
DPituitary corticotroph adenoma
EPrimary hypothyroidism
Why pituitary somatotroph adenoma is correct
This patient demonstrates the classic adult presentation of acromegaly: enlargement of acral parts (hands, feet, jaw), frontal bossing, macroglossia, and soft tissue overgrowth occurring after epiphyseal closure — almost always due to a growth hormone-secreting pituitary somatotroph adenoma
Diagnostic gold standard is failure of growth hormone to suppress below 1 ng/mL after a 75-gram oral glucose tolerance test, combined with an elevated age-adjusted IGF-1 — both present in this patient
Pituitary MRI is then obtained to localize the adenoma; first-line therapy is transsphenoidal resection
If growth hormone excess occurs before epiphyseal closure, the result is gigantism rather than acromegaly
Why the others are wrong
Pituitary corticotroph adenoma — (Cushing disease) produces central obesity, moon facies, purple striae, and proximal weakness from cortisol excess, not acral enlargement
Primary hypothyroidism — can cause a puffy, coarse appearance but does not enlarge the jaw or hands or elevate IGF-1; TSH would be high and free T4 low
Severe insulin resistance syndrome — can produce some acromegaloid soft-tissue features (pseudoacromegaly) but with normal GH and IGF-1 levels and a normal glucose suppression test
Pituitary lactotroph adenoma — a prolactinoma is the most common hormone-secreting pituitary adenoma and a large one can cause headaches, but prolactin excess in men produces low libido, erectile dysfunction, and hypogonadism rather than acral and jaw enlargement, and it neither elevates IGF-1 nor prevents growth hormone suppression after an oral glucose load
Question 7EndocrineMedium
A 35-year-old woman is evaluated after passing a kidney stone and is found on bone densitometry to have osteoporosis. Laboratory studies show serum calcium 11.8 mg/dL, phosphorus 2.1 mg/dL, intact parathyroid hormone 145 pg/mL (elevated), and a 24-hour urine calcium of 320 mg. Which of the following is the most likely diagnosis?
ATertiary hyperparathyroidism
BPrimary hyperparathyroidism
CMalignancy-associated hypercalcemia
DFamilial hypocalciuric hypercalcemia
ESecondary hyperparathyroidism
Reveal answer & full explanation
Correct answer: B — Primary hyperparathyroidism
ATertiary hyperparathyroidism
BPrimary hyperparathyroidism✓
CMalignancy-associated hypercalcemia
DFamilial hypocalciuric hypercalcemia
ESecondary hyperparathyroidism
Why Primary hyperparathyroidism is correct
Hypercalcemia (11.8 mg/dL) with an inappropriately elevated PTH (145 pg/mL) defines PTH-dependent hypercalcemia, and a parathyroid adenoma is the cause in roughly 85% of cases.
Excess PTH drives renal phosphate wasting (hypophosphatemia 2.1 mg/dL), increased bone resorption (osteoporosis), and hypercalciuria (urine calcium 320 mg/24h), producing this patient's stone and bone disease.
Why the others are wrong
Familial hypocalciuric hypercalcemia — also shows hypercalcemia with non-suppressed PTH but is defined by LOW urine calcium (calcium-to-creatinine clearance ratio typically <0.01); the elevated 24-hour urine calcium refutes it, a confused-with trap on 'high calcium, normalish PTH.'
Malignancy-associated hypercalcemia — PTHrP-mediated hypercalcemia suppresses PTH, so an elevated PTH excludes it; it is the premature-closure pick for any hypercalcemia.
Secondary hyperparathyroidism — a compensatory PTH rise to chronic hypocalcemia (renal failure, vitamin D deficiency) that presents with low or normal calcium, not hypercalcemia; buzzword-matching on 'high PTH.'
Tertiary hyperparathyroidism — also produces hypercalcemia with an elevated PTH, but it reflects autonomous parathyroid hyperplasia after long-standing secondary hyperparathyroidism, typically in chronic kidney disease or after kidney transplant; without that history, PTH-dependent hypercalcemia in a young woman with stones and osteoporosis is primary disease (confused-with trap on 'high calcium, high PTH').
Question 8EndocrineMedium
A 31-year-old woman has taken cabergoline 0.5 mg twice weekly for 2 years for a 6 mm prolactin-secreting pituitary adenoma; her prolactin normalized and her menses resumed on therapy. She has been trying to conceive, and a urine pregnancy test today is positive at an estimated 6 weeks of gestation by her last menstrual period. She reports no headache and no change in her vision. Which of the following is the most appropriate management at this point?
AContinue cabergoline at her current dose for the rest of the pregnancy
BStop cabergoline and obtain formal visual field testing each trimester
CSwitch from cabergoline to bromocriptine for the rest of the pregnancy
DStop cabergoline and ask about headache or visual change at each visit
EStop cabergoline and check a serum prolactin at each prenatal visit
Reveal answer & full explanation
Correct answer: D — Stop cabergoline and ask about headache or visual change at each visit
AContinue cabergoline at her current dose for the rest of the pregnancy
BStop cabergoline and obtain formal visual field testing each trimester
CSwitch from cabergoline to bromocriptine for the rest of the pregnancy
DStop cabergoline and ask about headache or visual change at each visit✓
EStop cabergoline and check a serum prolactin at each prenatal visit
Why Stop cabergoline and ask about headache or visual change at each visit is correct
Endocrine Society guidance is to discontinue the dopamine agonist as soon as pregnancy is confirmed in a woman with a microprolactinoma; the drug has already done its job of restoring ovulation, and there is no reason to prolong fetal exposure.
Symptomatic tumor enlargement during pregnancy occurs in only about 2-3% of microadenomas, so the appropriate safeguard is symptom-driven vigilance rather than continued drug therapy or scheduled testing.
Asking about new headache or visual change at each prenatal visit is the surveillance that actually changes management: either symptom prompts formal visual field testing, followed by MRI without gadolinium if the fields are abnormal or the symptoms persist, and a dopamine agonist is restarted only for confirmed symptomatic enlargement.
Inadvertent first-trimester exposure before the test turned positive is reassuring rather than alarming, since neither cabergoline nor bromocriptine has been linked to excess miscarriage or congenital malformation.
Why the others are wrong
Continue cabergoline at her current dose for the rest of the pregnancy - continuing a dopamine agonist through gestation is reserved for a large or invasive tumor with mass effect, where the risk of expansion outweighs the exposure; a 6 mm lesion carries only a 2-3% risk of symptomatic enlargement, so this prolongs fetal exposure to prevent an event that is both unlikely and treatable if it occurs (the trap is assuming a drug that is working should never be stopped).
Stop cabergoline and check a serum prolactin at each prenatal visit - the drug decision is right but the surveillance is uninterpretable: lactotroph hyperplasia raises prolactin severalfold in every normal pregnancy, so a rising level cannot distinguish tumor growth from physiology, and guidelines advise against measuring it during gestation.
Stop cabergoline and obtain formal visual field testing each trimester - scheduled perimetry during pregnancy is advised for macroadenomas, where the risk of symptomatic enlargement is far higher; in a 6 mm lesion it changes no decision, and the trigger for formal fields is a new symptom (the trap is applying the macroadenoma rule to a microadenoma).
Switch from cabergoline to bromocriptine for the rest of the pregnancy - bromocriptine has the larger pregnancy safety database, which makes switching agents feel like the cautious move, but a 6 mm microadenoma needs no dopamine agonist at all once pregnancy is confirmed, so changing drugs only prolongs fetal exposure; a dopamine agonist, either agent, is restarted only for confirmed symptomatic enlargement (the trap is changing the drug when the decision is to stop it).
Additional high-yield points
Risk of symptomatic enlargement in pregnancy is stratified by tumor size and prior therapy: roughly 2-3% for a microadenoma, about 5% for a macroadenoma previously treated with surgery or radiation, and roughly 20-30% for a macroadenoma not previously treated.
Bromocriptine has the larger pregnancy safety database (roughly 6,000 documented exposures versus about 1,000 for cabergoline), but current guidance treats either agent as acceptable when a dopamine agonist must be restarted during gestation.
Pituitary MRI in pregnancy is obtained without gadolinium and only for symptoms suggesting enlargement, never as routine surveillance.
After delivery, breastfeeding is safe with a microprolactinoma and does not stimulate tumor growth; a dopamine agonist suppresses lactation, so restarting it is usually deferred until nursing ends unless the tumor requires treatment.
Question 9EndocrineMedium
A 66-year-old man is evaluated for 2 months of palpitations, heat intolerance, a fine tremor of the outstretched hands, and a 6-kg weight loss. He has taken amiodarone 200 mg daily for 4 years for paroxysmal atrial fibrillation. Heart rate is 106/min and irregular, and blood pressure is 138/72 mm Hg. The thyroid is normal in size and contour, smooth, and nontender. TSH is less than 0.01 mIU/L, free T4 is 4.1 ng/dL (0.8-1.8), total T3 is 240 ng/dL (80-180), and serum thyroglobulin is 92 ng/mL (1.5-38). TSH receptor antibodies are undetectable. Color-flow Doppler ultrasonography of the thyroid shows normal gland architecture with absent intrathyroidal vascular flow. Which of the following is the most likely diagnosis?
AExogenous (factitious) thyrotoxicosis
BPainless (silent) lymphocytic thyroiditis
CType 1 amiodarone-induced thyrotoxicosis
DType 2 amiodarone-induced thyrotoxicosis
EAmiodarone-induced euthyroid hyperthyroxinemia
Reveal answer & full explanation
Correct answer: D — Type 2 amiodarone-induced thyrotoxicosis
AExogenous (factitious) thyrotoxicosis
BPainless (silent) lymphocytic thyroiditis
CType 1 amiodarone-induced thyrotoxicosis
DType 2 amiodarone-induced thyrotoxicosis✓
EAmiodarone-induced euthyroid hyperthyroxinemia
Why Type 2 amiodarone-induced thyrotoxicosis is correct
Amiodarone is about 37% iodine by weight, and a 200 mg daily dose releases roughly 7 mg of free iodide, some 50 times the daily requirement, so thyrotoxicosis appearing years into therapy is a drug effect until proven otherwise. The drug causes it by two different mechanisms, the hormone levels look the same in both, and the type has to be settled by the gland itself before anything is added.
Type 2 disease is a direct drug toxicity to follicular cells: the gland is destroyed rather than driven, preformed hormone leaks out of it, and new synthesis stops. A structurally normal, painless, non-enlarged gland with absent intrathyroidal flow on color-flow Doppler is the signature, because a gland that is not synthesizing hormone is not hyperemic.
The elevated thyroglobulin confirms that the circulating hormone is spilling out of a thyroid unloading its stores rather than arriving from outside the patient, and the disproportionately modest total T3 beside a markedly high free T4 is what amiodarone's block of 5'-deiodinase conversion does to the ratio.
Four years of exposure in a 66-year-old man is what makes the drug, rather than a coincidental autoimmune destructive thyroiditis, the explanation for the destruction: this is the epidemiology of amiodarone-induced disease, not of sporadic silent thyroiditis, and amiodarone-induced thyrotoxicosis develops in roughly 3% of treated patients in iodine-sufficient regions.
Typing the disease picks the drug: type 2 responds to an oral glucocorticoid such as prednisone 40 mg daily, while a thionamide is useless because there is no ongoing synthesis to block. A beta blocker controls adrenergic symptoms in either type, and many patients later pass through a hypothyroid phase.
In iodine-sufficient areas the 24-hour radioiodine uptake is low in both types, because the iodine load saturates the gland, so a low uptake confirms the setting but does not separate type 1 from type 2.
Why the others are wrong
Type 1 amiodarone-induced thyrotoxicosis - type 1 is iodine substrate driving excess synthesis in a gland that already harbors autonomous nodules or latent Graves tissue, so it shows a palpable multinodular or diffusely enlarged goiter with preserved-to-increased Doppler flow; a normal-sized smooth gland with no flow at all is a gland that has stopped making hormone, not one that iodine has pushed into overproduction, and the undetectable TSH receptor antibodies remove the latent-Graves substrate as well. The added drug for type 1 would be a thionamide such as methimazole rather than a glucocorticoid (the trap is stopping at amiodarone plus thyrotoxicosis without subtyping).
Painless (silent) lymphocytic thyroiditis - this is the one entity in the differential that no test result here separates from type 2 disease: it is also a painless destructive thyrotoxicosis with a normal-to-slightly-enlarged nontender gland, absent Doppler flow, low uptake, and an elevated thyroglobulin, and antibodies would not settle it either, since anti-thyroid peroxidase antibodies are positive in only about half of sporadic cases (about 80% in postpartum thyroiditis). The setting decides it: silent thyroiditis is classically postpartum or sporadic in younger women, whereas a 66-year-old man 4 years into amiodarone carries an exposure that explains follicular destruction directly, and type 2 disease is additionally treated with a glucocorticoid rather than managed supportively (the trap is stopping at destructive thyroiditis without asking what destroyed the gland).
Exogenous (factitious) thyrotoxicosis - ingested thyroid hormone also produces thyrotoxicosis with a normal, painless, avascular gland, which is exactly why it belongs in this differential and why history alone cannot exclude it; it suppresses endogenous production, so serum thyroglobulin is low or undetectable rather than elevated, and ingested levothyroxine characteristically raises T4 out of proportion to T3 (the trap is reading a normal avascular gland as automatically factitious).
Amiodarone-induced euthyroid hyperthyroxinemia - amiodarone's block of 5'-deiodinase commonly raises the free T4 in treated patients, so a high free T4 on this drug can look like an expected laboratory effect; but that benign pattern keeps the TSH normal or only transiently high and the T3 lowered, whereas a TSH below 0.01 mIU/L with an elevated total T3 and thyroglobulin, weight loss, and tremor is genuine thyrotoxicosis (the trap is dismissing every high free T4 on amiodarone as a drug artifact).
Additional high-yield points
Thyroglobulin is elevated in both types of amiodarone-induced thyrotoxicosis and in silent thyroiditis, so it does not subtype the disease; its job is to separate hormone released from a thyroid from hormone swallowed by the patient.
An iodine load can precipitate hyperthyroidism in a gland that carries latent Graves disease, but Graves disease drives the gland rather than destroying it and produces a diffusely enlarged, hypervascular thyroid with detectable TSH receptor antibodies; when an iodine load genuinely does unmask latent Graves tissue in an amiodarone-treated patient, the result is classified and managed as type 1 disease.
Mixed and indeterminate forms are common, and when the gland exam and the Doppler study do not settle the type it is accepted practice to start methimazole and prednisone together and reassess in 2 to 4 weeks (European Thyroid Association 2018).
Whether to stop amiodarone is a cardiology decision separate from which drug to add, and stopping helps slowly at best: the elimination half-life is roughly 50 to 100 days, so treatment is started regardless. Radioiodine ablation cannot be used in either type because uptake is too low for it to work.
Amiodarone more often causes hypothyroidism, especially in iodine-sufficient regions, through a Wolff-Chaikoff effect the gland fails to escape; that is treated with levothyroxine and usually does not require stopping the drug.
Do not confuse thyrotoxicosis with amiodarone's benign biochemical effect: by inhibiting 5'-deiodinase the drug commonly raises free T4 and lowers T3 with a normal or transiently high TSH. A suppressed TSH beside a frankly elevated T3, as here, is real thyrotoxicosis. Check TSH before starting amiodarone and about every 6 months thereafter.
Question 10EndocrineMedium
A 45-year-old woman reports several months of mild fatigue. She has no goiter, weight change, or cold intolerance. Thyroid studies show a TSH of 8.2 mIU/L (reference 0.4–4.0) with a normal free T4, and anti-thyroid peroxidase (anti-TPO) antibodies are positive. Which of the following is the most likely diagnosis?
AEuthyroid sick syndrome
BOvert primary hypothyroidism
CSubclinical hypothyroidism
DSecondary hypothyroidism
ESubclinical hyperthyroidism
Reveal answer & full explanation
Correct answer: C — Subclinical hypothyroidism
AEuthyroid sick syndrome
BOvert primary hypothyroidism
CSubclinical hypothyroidism✓
DSecondary hypothyroidism
ESubclinical hyperthyroidism
Why subclinical hypothyroidism is correct
Subclinical hypothyroidism is defined as an elevated TSH with a normal free T4, exactly the pattern here.
Positive anti-thyroid peroxidase antibodies identify Hashimoto (autoimmune) thyroiditis as the underlying cause and predict progression to overt disease.
The mild, nonspecific fatigue without overt hypothyroid signs fits a subclinical (biochemical) stage.
Why the others are wrong
Euthyroid sick syndrome — occurs in acutely ill patients and typically shows a low or normal TSH with low T3/T4; there is no acute illness here, so this is buzzword-matching on "abnormal thyroid tests."
Secondary hypothyroidism — central (pituitary/hypothalamic) hypothyroidism produces a low or inappropriately normal TSH with a low free T4, the opposite of the high TSH seen here.
Subclinical hyperthyroidism — defined by a suppressed (low) TSH with a normal free T4; the elevated TSH here is the mirror-image (confused-with the opposite biochemical pattern).
Overt primary hypothyroidism — positive anti-TPO antibodies and fatigue point to Hashimoto thyroiditis, which tempts a diagnosis of established hypothyroidism, but overt primary hypothyroidism requires a low free T4 alongside the high TSH; with a normal free T4 the gland is still compensating under TSH drive, which is the subclinical stage (the trap is equating autoimmune thyroiditis with overt gland failure).
Additional high-yield points
Treat subclinical hypothyroidism when TSH is >10 mIU/L; consider treatment when the patient is symptomatic, planning pregnancy, or anti-TPO positive with a clearly rising TSH. In pregnancy (ATA 2026), mild subclinical hypothyroidism is treated only selectively (considered if found in the first trimester and confirmed on repeat testing).
That's 10 of 7,700+. Get the rest.
Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
Are these Endocrinology PANCE practice questions free?
Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.
How much of the PANCE is Endocrinology?
Endocrinology makes up 6% of the PANCE content blueprint. FirstPassPA's timed PANCE exams are dealt to the same weights, so a practice exam carries the same share of Endocrinology questions.
How should I use these questions?
Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Endocrinology questions in the app, or take a full timed PANCE practice exam dealt to the blueprint weights.
Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.